Chemical structures and pKa values (prediction from ChemAxon software) of the small molecules and drugs used in this study.

LogP, pKa and lysosomal sequestration of drugs used in this study (Predicted by ChemAxon software, and obtained from drug bank data base

(Zhitomirsky and Assaraf, 2015))

Diffusion coefficients of proteins and small molecules in the HeLa cells.

Comparison of diffusion coefficients (Dconfocal in blue circles) and percentage of recoveries (in red squares) of bacterial proteins and BSA as measured in HeLa cell cytoplasm are shown. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Fluorescein, CCF2 and CF514 diffusion in PBS and inside HeLa cells.

Comparative averaged FRAP profiles (N= 30; R= 0.99 for each of the fits) in PBS and inside HeLa cells with exponential fits are shown for (A) Fluorescein, (D) CCF2 and (G) CF514. Comparative Dconfocal values for (B) Fluorescein (E) CCF2 and (H) CF514 are also shown. HeLa cells after Micro-injection are shown in (C) for Fluorescein (F) for CCF2 and (I) for CF514. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Diffusion of GSK3 inhibitor in PBS and inside HeLa cells.

Comparative (A) averaged FRAP recovery profiles with exponential fits for GSK3 inhibitor (SB216763) (N= 30; R= 0.99 for each of the fits). Dots show prebleach fluorescence, Black line for DMEM, blue for PBS buffer + 50 mg/mL of BSA, green for HeLa cells and orange for HeLa extract. (B) Averaged bleach size profiles with gaussian fits (N= 30; R= 0.99 for each of the fits) and (C) Calculated Dconfocal values. (D-E) Colocalization of GSK3 inhibitor in lysosomal compartments. HeLa cells were treated with Lyso Tracker 633 for 30 mins. GSK3 inhibitor treatment for (D) 45 mins and (E) 2 hours respectively at 10 µM concentrations are also shown. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Diffusion of Quinacrine in PBS and in HeLa cells.

Comparative (A) averaged FRAP recovery profiles with exponential fits for Quinacrine dihydrochloride (N= 30; R= 0.99 for each of the fits), (B) averaged bleach size profile with gaussian fits (N= 30; R= 0.99 for each of the fits) and (C) diffusion coefficients in PBS buffer, in 50mg/mL of BSA, HeLa cell extract and in live HeLa cells are shown. (D-E) Colocalization of Quinacrine DHC in lysosomal compartments are shown. HeLa cells were treated with Lyso Tracker 633 for 30 mins. Quinacrine DHC treatment was done for (D) 45 mins and (E) 2 hours respectively at 10 µM concentration. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Mitoxantrone and Primaquine diffusion inside HeLa cells.

Averaged XY-FRAP recovery profiles with exponential fits (N= 20; R= 0.98 for each of the fits) for (A) Mitoxantrone and (E) Primaquine in HeLa cells. Fluorescent and Transmission channel images of HeLa cells after 45 mins incubations with (B-C) Mitoxantrone and (F-G) Primaquine are shown. Time lapse micrographs of a portion of HeLa cell going through a classical rectangular XY-FRAP protocol for (D) Mitoxatrone and, (H) Primaquine are also shown.

Effect of Sodium Azide on the diffusion of GSK3 inhibitor and Quinacrine inside HeLa cells.

(A) GSK3 inhibitor and (D) Quinacrine dihydrochloride treated HeLa cells with or without sodium azide. Comparison of averaged FRAP profiles with exponential fits (N= 30; R= 0.99 for each of the fits) and calculated Dconfocal values for (B-C) GSK3 inhibitor and (E-F) Quinacrine dihydrochloride. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

FRAP of Fluorescein analogues inside HeLa cells.

(A) Structures of Fluorescein analogues with pKa values. (B) FRAP recoveries with exponential fits for Fluorescein, CCF2 and 5-amino Fluorescein, with/without Na-Azide treatments in HeLa cells (N= 30; R= 0.99 for each of the fits). (C) Line FRAP profiles with time lapses. (D) Micrograph images of treated HeLa cells after small molecule incubations.

Oligomeric state, Isoelectric point and Net charge at pH 7.4

Key resources table

FRAP measurements for Fluorescein following different incubation times.

Micrographs of HeLa cells (A) instantaneously after micro-injection vs (B) FRAP after 24 hours incubation are shown. Comparative (C) averaged FRAP profiles with fits (N= 30; R= 0.99 for each of the fits) and (D) their Dconfocal values. (E-F) Comparative UV spectrum of CF514 labelling dye in 20 mM sodium phosphate buffer at different pH values, from which a pKa value of 3 was calculated. Error bars represent SE calculated from fitting the FRAP progression curves averaged over at least 30 independent measurements.

Diffusion rates at different doses of GSK3 inhibitor inside HeLa.

(A-B) Drug dose dependency of GSK3 inhibitor treated HeLa cells. Effect of drug dosage (2-10 µM) on (A) averaged FRAP profiles with fits (N= 30; R= 0.99 for each of the fits) and (B) Dconfocal values. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Quinacrine diffusion in HeLa after micro-injection or incubation.

Comparison of FRAP immediately following micro-injection (instant FRAP) and FRAP following 2-24 hr incubation. HeLa cell micrographs following (A) micro-injection and (B) 2 hours of incubation. Comparative (C) averaged FRAP profiles with exponential curve fits (N= 30; R= 0.99 for each of the fits) and (D) calculated Dconfocal values. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Dose and time dependency of Quinacrine diffusion in HeLa cells.

HeLa cell micrographs after 2 hours of incubation with (A) 2 µM and (B) 6 µM of Quinacrine. (C) and (D) are micrographs of HeLa cells after 24 hours of incubation with 2 µM and 6 µM Quinacrine respectively. (E) Effect of drug dose and time dependency on comparative FRAP profiles, with fits (N= 30; R= 0.99 for each of the fits) and (F) Calculated Dconfocal values from the fits in (E). Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Colocalization of Primaquine and Amidoqiuine with Lyso-tracker.

Colocalization of Primaquine (A-B) and Amidoquine (C-D) with Lyso Tracker 633 in HeLa cells. Time dependent measurements show higher aggregation of both drugs in the lysosomes over time.

Diffusion coefficients of small molecules in PBS buffer and inside HeLa cells.

Comparison of Dconfocal values of small molecule drugs in (A) PBS buffer and in (B) HeLa cells. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Inhibition of lysosomal accumulation of GSK3 inhibitor by Bafilomycin A.

(A-B) Colocalization of GSK3 inhibitor with Lyso Tracker 633 in HeLa cells. (A) Untreated and (B) treated with 100 nM Bafilomycin A1 and corresponding colocalizations are shown. (C) Comparative averaged FRAP profiles with fits (N= 30; R= 0.99 for each of the fits) and (D) Dconfocal diffusion values with and without the Bafilomycin A1 treatment. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Inhibition of lysosomal accumulation of Quinacrine by Bafilomycin A.

(A-B) Colocalization of Quinacrine with Lyso Tracker 633 in HeLa cells. HeLa cells (A) untreated and (B) treated with 100 nM Bafilomycin A1 and corresponding colocalizations. (C) Comparative averaged FRAP profiles with fits (N= 30; R= 0.99 for each of the fits) and (D) Dconfocal values with and without the Bafilomycin A1 treatment. Error bars represent SE calculated from fitting the FRAP progression curves, which are averaged over at least 30 independent measurements.

Comparative FRAP of Primaquine analogues inside HeLa cells.

(A) Structures of Primaquine analogues with pKa values. Comparative (B-D) XY FRAP micrographs with time lapses in HeLa cell. (E-H) Micrographs of treated HeLa cells either with micro-injection or after drug incubations with Prim or Prim-Ac. Comparative (I) XY-FRAP recovery profiles with fits (N= 20; R= 0.98 for each of the fits) and (J) percentage of recoveries for Primaquine analogues in HeLa cytoplasm (N= 20).

Comparative FRAP of BODIPY analogues inside HeLa cells.

(A) Structures of BODIPY analogues. (B-C) Comparative XY FRAP micrographs with time lapses in HeLa cell cytoplasm. (D-G) Micrographs of treated HeLa cells after incubations (with BDP/BDP-Ac) and, Comparative (H) averaged XY-FRAP recovery profiles with fits (N= 30; R= 0.99 for each of the fits), (I) averaged half-life and percentage of recoveries for BODIPY analogues in HeLa cytoplasm (H) (N= 30).

Time dependent colocalization of GSK3 inhibitor and Nile Red inside HeLa cells.

Panels (A-C) show Nile red accumulating in lipid droplets, while GSK3 inhibitor does not colocalize.

Time dependent colocalization of GSK3 inhibitor and ER marker inside HeLa cells.

Panels (A-D) show BFP/mCherry fused antibody marker accumulating in ER, but GSK3 inhibitor does not colocalize. HeLa cells were first transiently transfected with BFP/mCherry fused antibody markers, then treated with GSK3 inhibitor.

Time dependent colocalization study of Mitoxantrone and SYTO blue marker inside HeLa cells.

Panels (A-B) show SYTO blue marker accumulating in nucleic acids, but Mitoxantrone is not colocalized. HeLa cells were first treated with SYTO blue, then treated with Mitoxantrone.

Super resolution images of GSK3 inhibitor treated HeLa cells.

Micrographs were taken using a Zeiss LSM900 microscope.

Evaluating channel leakage.

Control experiments showing that channel leakage did not occur during colocalization studies. (A) Lyso-Tracker only, (B) Quinacrine only and (C) Mitoxantrone only.

Characterization of Primaquine (Prim) and N-acetylated Primaquine (PrimAc).

(A) Absorption (c ≈ 1 · 10-3) and (B) emission (c ≈ 3 · 10-4) spectra. Both experiments were measured in the mixture of 10% DMSO in PBS or in Glycine/NaOH buffer. (C) Measurement of hydrolytic stability by HPLC. (D) HPLC-MS measurement of PrimAc are shown. According to HPLC-MS data the peak at 7.125 corresponds to 302 m/z (ESI +) so as the main peak at 7.296. The molar mass of PrimAc corresponds to the measured value.

N-acetylated Primaquine.

(A) 1H NMR spectrum is shown. The presence of impurities is caused by the degradation in the used solvent. (B) 13C NMR spectrum is shown.

N-acetylated Primaquine.

HRMS spectrum (+EI) is shown.

(A) Structure and photo-physical properties of BODIPY analogues. (B) Absorption (full line) and emission spectra (dashed line) of BDP-NH2 in DMSO (black) and PBS (red) are shown. (C) Absorption (full line) and emission spectra (dashed line) of BDP-NHAc in DMSO (black) and PBS (red) are shown.

Characterization of BODIPY-NH2.

(A) 1H NMR spectrum and (B) 13C NMR spectrum are shown.

BODIPY-NH2.

HRMS spectrum (+EI) is shown.

Characterization of BODIPY-NHAc.

(A) 1H NMR spectrum and (B) 13C NMR spectrum are shown.

BODIPY-NHAc.

HRMS spectrum (+EI) is shown.